NewsBenzingaC4 테라퓨틱스, 제23회 IMS 연례 학술대회에서 RRMM 환자 대상 덱사메타손 병용 세미시도마이드 1상 임상시험의 새로운 바이오마커 데이터 발표 C4 테라퓨틱스, 제23회 IMS 연례 학술대회에서 RRMM 환자 대상 덱사메타손 병용 세미시도마이드 1상 임상시험의 새로운 바이오마커 데이터 발표 Benzinga 2026.09.25 11:02 (GMT+0) Open on Benzinga Other news 'Europe’s Top Carriers Explore Satellite Group to Fend Off SpaceX' - Bloomberg HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target Reported October 16, 'CFP reaches 'handshake agreement' with ESPN to air 24-team playoff, sources say' - ESPN HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73 Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target AI Boom Hits a Power Wall: Microsoft Walks Away From Nscale's UK Data Center Deal
Reported October 16, 'CFP reaches 'handshake agreement' with ESPN to air 24-team playoff, sources say' - ESPN